Evolution Credit Partners’ Post

If you are over 45, and haven't been screened or unsure if you are due to be screened, speak to your healthcare provider and discuss options. Please get screened. Early detection is important

Find out your risk and when you should be screened.

Suppose that everything we do today with precision oncology in the clinic is "low-hanging fruit". We deploy a kinase inhibitor against cancers where that specific kinase has a known oncogenic mutation, we deploy an antibody to block a receptor on cancers where that receptor is highly overexpressed, etc. There are situations where a single therapy directed at a single target does shrink tumors and improve survival for cancer patients. But there are many situations where there is no clear biomarker, and/or there is no safe and effective therapy. What will it take to reach the higher branches of the tree? Do we need to identify cancer subtypes defined not by one mutation in one gene, but patterns of altered biology? Perhaps this will open opportunities for existing drug modalities or even existing drugs to provide benefit to patients not previously identifiable. Do we need to develop new treatment modalities to address known targets, perhaps previously "undruggable" targets that are known to occur frequently in human cancers? What scientific and technological advances are required for each approach? What are the people requirements--talent, teams, and collaborations--to achieve those advances? And what can be done to manage the complexity of new advances, to make them accessible broadly? The 6th annual Emerging Frontiers in Oncology Summit will explore these topics with an incredible panel of research leaders, biopharma executives, investors, and entrepreneurs. Please join us to partake in an important conversation, and to support the Damon Runyon foundation in its important work!

Looking forward to the "debate", Kapil Dhingra. Let's see where we all land on balancing a move to increasing our understanding of a patient's particular tumor, with precision of the diagnostics and patient segmentation that implies, versus the advancing of therapeutics that obviate the need for such by their broadness of activity while maintaining a good therapeutic index (like ADCs?), or actually are therapies that are multifunctional to address the heterogeneity and plasticity of the cancer.

🎀 It’s #TimeToEndBreastCancer Today, breast cancer remains the most commonly diagnosed cancer in women worldwide. This October, I’m partnering with Marion Pelzel and my colleagues at @The Estée Lauder Companies for the Breast Cancer Campaign. For over 32 years, the company has been committed to funding research, education, and medical services to help end breast cancer for all. 💡 By sharing our photo, we highlight that breast cancer connects us all and impacts all generations. Early detection can save lives —schedule your check-up, learn the signs, and share your knowledge. Let’s take action together. Learn more here: https://lnkd.in/dxh5VHZi or https://lnkd.in/d7kWfB8J Donate to the cause: 👉 https://lnkd.in/d23nmNPz #TimetoEndBreastCancer #ELCBreastCancerCampaign #StrongerTogether #ELC Employee

03/03 World Triple-Negative Breast Cancer (TNBC) Day 🎗 TNBC is a subtype of breast cancer representing about 10-15% of all cases and tends to be more aggressive and have a poorer prognosis compared to other types of breast cancer. Early diagnosis and treatment are crucial due to its rapid progression. At Firalis Molecular Precision, we're committed to raising awareness of #TNBC and supporting efforts to find effective treatments. Our advanced platforms and scientific expertise in NGS, Spatial Transcriptomics, Single-cell Sequencing, and custom RT-qPCR, enable biopharmaceutical organizations, researchers, and #healthcare professionals to understand the complexities of TNBC and discover novel treatment strategies. By collaborating, leveraging cutting-edge technologies and relying on our experts know-how, we can accelerate the development of targeted therapies and improve outcomes for patients affected by this challenging disease. https://lnkd.in/e9W3beMq.

Here's the original post from our friends at DELFI Diagnostics - together, we are changing the culture of healthcare.

🎄✌️🚨New Year report on OncoDaily :) This is a screenshot from LinkedIn - the Total Engagement Metrics for the last 30 days. It is such a great honor and pleasure, that people like what we are doing. In a very short period of time OncoDaily became one of the leading and one of the fastest growing media platforms in the oncology world! This is a team effort - a great group of like-minded enthusiasts, who are trying to raise the voice of the people in oncology, to be the "voice of oncology". Our motto is "Cancer doesn't take a day off: Neither do we". Join our movement, be the voice of oncology! #Oncology #Cancer #OncoDaily

📣 We are thrilled to announce that our NEO-IMPACT pancreatic cancer clinical trial has achieved its recruitment target. Any trial completing recruitment is a milestone worth celebrating, but NEO-IMPACT is our first ever clinical trial funded entirely by the community and philanthropy, which makes it extra special! The trial aims to investigate the efficacy, safety and tolerability of combining chemotherapy and immunotherapy prior to surgery for early-stage pancreatic cancer treatment. As pancreatic cancer patients usually only have 6–12 months to live from their diagnosis, this study could have a significant impact and hopefully bring effective new treatments to these patients. As the Study Chair, Professor Lorraine Chantrill, highlights in this thank you video, we could not have made this study a reality without the help of 413 incredible donors, giving 618 individual donations, from $2 to $150,000. We thank them all for their invaluable support and contribution ❤️ WEHI (Walter and Eliza Hall Institute of Medical Research) #AGITG #ClinicalTrial #CancerResearch #GICancer

🚨 EOFY is tomorrow! Don’t miss your opportunity to contribute to cutting-edge melanoma and skin cancer clinical trials. By donating, you're supporting innovative research that can help melanoma patients like Ana Ratapu. When Ana was diagnosed with metastatic melanoma, she had to fight to access a clinical trial that could save her life. Now, Ana is working with us to advocate for clinical trials and help remove the barriers other melanoma patients may face. Please make a tax-deductible donation before midnight on 30 June 2024 to help conquer melanoma and skin cancer. Learn more and donate at https://lnkd.in/ehdjqVA9 #melanoma #skincancer #melanomawarrior #melanomaawareness #melanomasurvivor #melanomaprevention #melanomaresearch #melanomasupport #clinicaltrials #clinicalresearch #supportresearch #donate